{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:05:59Z","timestamp":1791162359385,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.clinthera.2008.01.014","type":"journal-article","created":{"date-parts":[[2008,4,17]],"date-time":"2008-04-17T11:11:31Z","timestamp":1208430691000},"page":"14-30","source":"Crossref","is-referenced-by-count":52,"title":["Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Mei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Rivkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinh","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.01.014_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2008.01.014_bib2","author":"Engstrom"},{"key":"10.1016\/j.clinthera.2008.01.014_bib3","author":"Engstrom"},{"key":"10.1016\/j.clinthera.2008.01.014_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2008.01.014_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.01.014_bib6","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.01.014_bib7","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","article-title":"Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment","volume":"22","author":"Grothey","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib8","series-title":"Vectibix (panitumumab) [package insert]","year":"2006"},{"key":"10.1016\/j.clinthera.2008.01.014_bib9","series-title":"Erbitux (cetuximab) [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2008.01.014_bib10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1586\/14737140.6.6.921","article-title":"First- and second-line therapy of metastatic colorectal cancer","volume":"6","author":"Terstriep","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2008.01.014_bib11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3816\/CCC.2005.s.003","article-title":"Epidermal growth factor receptor as a target for chemotherapy","volume":"5","author":"Vallbohmer","year":"2005","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2008.01.014_bib12","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.3816\/CCC.2005.s.011","article-title":"Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer","volume":"5","author":"Chua","year":"2005","journal-title":"Clin Colorectal Cancer."},{"key":"10.1016\/j.clinthera.2008.01.014_bib13","first-page":"364","article-title":"Antibody-based cancer drugs: Developing antibody therapeutic approaches to deliver individualized cancer drugs","volume":"8","author":"Kalland","year":"2005","journal-title":"IDrugs"},{"key":"10.1016\/j.clinthera.2008.01.014_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2007.02.006","article-title":"Cellular responses to EGFR inhibitors and their relevance to cancer therapy","volume":"254","author":"Dutta","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clinthera.2008.01.014_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pharmthera.2004.01.002","article-title":"Signaling through the epidermal growth factor receptor during the development of malignancy","volume":"102","author":"Grandis","year":"2004","journal-title":"Pharmacol Their"},{"key":"10.1016\/j.clinthera.2008.01.014_bib16","first-page":"987","article-title":"Targeted therapies in cancer-Fourth International Congress. Epidermal growth factor receptor blockade and immune modulation","volume":"8","author":"Tawbi","year":"2005","journal-title":"IDrugs."},{"key":"10.1016\/j.clinthera.2008.01.014_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CCC.2006.n.028","article-title":"Role of panitumumab in the management of metastatic colorectal cancer","volume":"6","author":"Saif","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clinthera.2008.01.014_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","article-title":"Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer","volume":"6","author":"Gibson","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clinthera.2008.01.014_bib19","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1200\/JCO.2005.10.951","article-title":"Epidermal growth factor receptor inhibitors in colorectal cancer: It's time to get back on target","volume":"23","author":"Meropol","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of pani-tumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1006384521198","article-title":"Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results","volume":"17","author":"Huang","year":"1999","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2008.01.014_bib24","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.clinthera.2008.01.014_bib25","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: Receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.clinthera.2008.01.014_bib26","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2008.01.014_bib27","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2008.01.014_bib28","first-page":"2313","article-title":"Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification","volume":"9","author":"Ekstrand","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.clinthera.2008.01.014_bib29","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M","article-title":"Epidermal growth factor receptor immunohis-tochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system","volume":"92","author":"Goldstein","year":"2001","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2008.01.014_bib30","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1369\/jhc.3A6195.2004","article-title":"Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: Variation in staining intensity due to choice of fixative and storage time of tissue sections","volume":"52","author":"Atkins","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.clinthera.2008.01.014_bib32","series-title":"Presented at: 2006 ASCO Annual Meeting","article-title":"Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1\u20139%) or negative (<1%) levels of epidermal growth factor receptor (EGFr)","author":"Hecht","year":"2006"},{"key":"10.1016\/j.clinthera.2008.01.014_bib33","series-title":"Presented at: 2006 ASCO Annual Meeting","article-title":"Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing \u226710% epidermal growth factor receptor (EGFr)","author":"Berlin","year":"2006"},{"key":"10.1016\/j.clinthera.2008.01.014_bib34","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.2006.06.2067","article-title":"Progress with biological agents in metastatic colorectal cancer leads to many challenges","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib35","series-title":"Presented at: 1999 ASCO Annual Meeting","article-title":"Potent anti-tumor activity of ABX-EGF, a fully human monoclonal antibody to the epidermal growth factor receptor","author":"Yang","year":"1999"},{"key":"10.1016\/j.clinthera.2008.01.014_bib36","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2165\/00003495-200666150-00011","article-title":"Panitumumab: In the treatment of metastatic colorectal cancer","volume":"66","author":"Hoy","year":"2006","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2008.01.014_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/CAD.0b013e32800feecb","article-title":"Panitu-mumab the first fully human mono-clonal antibody: From the bench to the clinic","volume":"18","author":"Cohenuram","year":"2007","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clinthera.2008.01.014_bib39","series-title":"Presented at: 2007 Gastrointestinal Cancers Symposium","article-title":"Safety and pharmacokinetics (PK) of pani-tumumab in Japanese patients (pts) with advanced solid malignancies","author":"Yamada","year":"2007"},{"key":"10.1016\/j.clinthera.2008.01.014_bib40","series-title":"Presented at: 2002 ASCO Annual Meeting","article-title":"ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: Phase 1 clinical results","author":"Figlin","year":"2002"},{"key":"10.1016\/j.clinthera.2008.01.014_bib41","series-title":"Presented at: 2005 ASCO Annual Meeting","article-title":"Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies","author":"Weiner","year":"2005"},{"key":"10.1016\/j.clinthera.2008.01.014_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer."},{"key":"10.1016\/j.clinthera.2008.01.014_bib43","series-title":"Presented at: 2003 ASCO Annual Meeting","article-title":"Multicenter study of ABX-EGF mono-therapy in patients with metastatic colorectal cancer","author":"Meropol","year":"2003"},{"key":"10.1016\/j.clinthera.2008.01.014_bib45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib46","series-title":"Presented at: 2004 ASCO Annual Meeting","article-title":"ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis","author":"Hecht","year":"2004"},{"key":"10.1016\/j.clinthera.2008.01.014_bib47","series-title":"Presented at: 2005 ASCO Annual Meeting","article-title":"Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)","author":"Malik","year":"2005"},{"key":"10.1016\/j.clinthera.2008.01.014_bib48","series-title":"Presented at: 2007 Gastrointestinal Cancers Symposium","article-title":"Panitumumab activity in metasta-tic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis","author":"Hecht","year":"2007"},{"key":"10.1016\/j.clinthera.2008.01.014_bib49","series-title":"Presented at: 2006 Gastrointestinal Cancers Symposium","article-title":"Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC)","author":"Hecht","year":"2006"},{"key":"10.1016\/j.clinthera.2008.01.014_bib50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3816\/CCC.2006.n.008","article-title":"A phase III randomized, open-label, controlled trial of chemotherapy and bevacizu-mab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer","volume":"5","author":"Wainberg","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clinthera.2008.01.014_bib52","author":"Hecht"},{"key":"10.1016\/j.clinthera.2008.01.014_bib55","series-title":"Presented at: 2004 ASCO Annual Meeting","article-title":"ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC)","author":"Crawford","year":"2004"},{"key":"10.1016\/j.clinthera.2008.01.014_bib56","series-title":"Presented at: 2007 Gastrointestinal Cancers Symposium","article-title":"A phase III randomized controlled trial of panitumumab (Pmab) in pa-tients (pts) with metastatic colorec-tal cancer (mCRC): Subset analyses in elderly pts and in pts with poor performance","author":"Van Cutsem","year":"2007"},{"key":"10.1016\/j.clinthera.2008.01.014_bib57","series-title":"Presented at: 2005 Gastrointestinal Cancers Symposium","article-title":"Panitumumab therapy with irinote-can, 5-fluorouracil, and leucovorin (IFL) in metastatic colorectal cancer (mCRC) patients: A pharmacokinetic (PK) analysis","author":"Hecht","year":"2005"},{"key":"10.1016\/j.clinthera.2008.01.014_bib58","series-title":"Presented at: 2006 ASCO Annual Meeting","article-title":"Safety and pharmacokinetics (PK) of AMG 706, panitu-mumab, and carboplatin\/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)","author":"Blumenschein","year":"2006"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2008.01.014_bib59","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.3816\/CCC.2005.s.010","article-title":"Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer","volume":"5","author":"Snyder","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clinthera.2008.01.014_bib60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reactions in cancer patients receiving epi-dermal growth factor receptor targeted therapies","volume":"3","author":"Segaert","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clinthera.2008.01.014_bib61","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [published correction appears in J Clin Oncol. 2005;23:6281]","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib62","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol."},{"key":"10.1016\/j.clinthera.2008.01.014_bib63","series-title":"Presented at: 2005 ASCO Annual Meeting","article-title":"Flexible dosing schedules of panitu-mumab (ABX-EGF) in cancer patients","author":"Arends","year":"2005"},{"key":"10.1016\/j.clinthera.2008.01.014_bib64","series-title":"Presented at: 2007 Gastrointestinal Cancers Symposium","article-title":"Administration of panitumumab (Pmab) as a 30-min or 60-min infusion: Safety and pharmacokinetics (PK) from a phase 1 study in patients (pts) with solid tumors","author":"Stephenson","year":"2007"},{"key":"10.1016\/j.clinthera.2008.01.014_bib65","first-page":"10","article-title":"Defining the role of panitumumab in colorectal cancer","volume":"3","author":"Grothey","year":"2006","journal-title":"Community Oncol"},{"key":"10.1016\/j.clinthera.2008.01.014_bib66","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808000623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T20:50:17Z","timestamp":1546116617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808000623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0149291808000623"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.01.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}